[go: up one dir, main page]

MX9702861A - Metodo para inhibir las condiciones asociadas con la bradicinina. - Google Patents

Metodo para inhibir las condiciones asociadas con la bradicinina.

Info

Publication number
MX9702861A
MX9702861A MX9702861A MX9702861A MX9702861A MX 9702861 A MX9702861 A MX 9702861A MX 9702861 A MX9702861 A MX 9702861A MX 9702861 A MX9702861 A MX 9702861A MX 9702861 A MX9702861 A MX 9702861A
Authority
MX
Mexico
Prior art keywords
bradykinin
conditions associated
inhibiting conditions
inhibiting
hexamethyleneimino
Prior art date
Application number
MX9702861A
Other languages
English (en)
Other versions
MXPA97002861A (es
Inventor
Robert Frederick Bruns Jr
Donald Richard Gehlert
James Jeffry Howbert
William Henry Walker Lunn
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9702861A publication Critical patent/MX9702861A/es
Publication of MXPA97002861A publication Critical patent/MXPA97002861A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Se describe un método para inhibir una condicion fisiologica asociada con un exceso de bradicinina, que comprende el administrar a un humano en necesidad del mismo, una cantidad efectiva de un compuesto que tiene la formula (I), en donde R1 y R3 son independientemente hidrogeno, -CH3, (a) o (b), en donde Ar es fenilo opcionalmente substituido; R2 se selecciona del grupo que consiste de pirrolidino, hexametilenimino y piperidino; o una sal o solvato farmcéuticamente aceptable del mismo.
MXPA/A/1997/002861A 1994-10-20 1997-04-18 Metodo para inhibir las condiciones asociadas conla bradicinina MXPA97002861A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/326,672 US5545641A (en) 1994-10-20 1994-10-20 Methods of inhibiting physiological conditions associated with an excess of bradykinin
US08326672 1994-10-20
PCT/US1995/013452 WO1996012491A1 (en) 1994-10-20 1995-10-19 Method of inhibiting conditions associated with bradykinin

Publications (2)

Publication Number Publication Date
MX9702861A true MX9702861A (es) 1997-07-31
MXPA97002861A MXPA97002861A (es) 1997-12-01

Family

ID=

Also Published As

Publication number Publication date
AU714789B2 (en) 2000-01-13
EP0782444A4 (en) 2002-01-30
CZ119197A3 (en) 1997-11-12
NO971794D0 (no) 1997-04-18
US5545641A (en) 1996-08-13
FI971675A (fi) 1997-06-16
IL115614A (en) 1999-08-17
JPH10507760A (ja) 1998-07-28
ZA958683B (en) 1997-04-14
IL115614A0 (en) 1996-01-19
WO1996012491A1 (en) 1996-05-02
NO971794L (no) 1997-05-22
EP0782444A1 (en) 1997-07-09
NZ296285A (en) 2000-08-25
KR970706819A (ko) 1997-12-01
HUT77765A (hu) 1998-08-28
CA2203914A1 (en) 1996-05-02
FI971675A0 (fi) 1997-04-18
AU4003995A (en) 1996-05-15
RU2181047C2 (ru) 2002-04-10
MY113406A (en) 2002-02-28

Similar Documents

Publication Publication Date Title
IL112048A0 (en) Methods of inhibiting thrombin
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
AU7578794A (en) Methods for inhibiting endometriosis
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
MY112973A (en) Methods for inhibiting vascular smooth muscle cell migration
ZA9410094B (en) Method of increasing libido in post-menopausal women
UA27910C2 (uk) Засіб для підвищення експресії тромбомодуліну та підвищення активації протеїну с
MX9701334A (es) Metodos para inhibir la degeneracion de protesis oseas.
MX9709466A (es) Medicamento para inhibir el melanoma.
EA199700136A1 (ru) Способы ингибирования экзогенных эстрогенов
MX9701333A (es) Metodos para inhibir el daño neuronal.
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
PH31440A (en) Method of inhibiting hirsutism and alopecia in women.
MX9701332A (es) Metodos para curar y reparar fracturas oseas.
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
MX9701359A (es) Metodos para la inhibicion de la hiperplasia endometrial primaria.
MX9702853A (es) Metodos para inhibir condiciones asociadas con el neuropeptido "y".
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9706072A (es) Metodos de inhibicion de la adhesion celula-celula.
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees